A peroxisome proliferator-activated receptor gamma (PPARG) polymorphism is associated with zoledronic acid-related osteonecrosis of the jaw in multiple myeloma patients: analysis by DMET microarray profiling
- PMID: 21517810
- PMCID: PMC3638364
- DOI: 10.1111/j.1365-2141.2011.08622.x
A peroxisome proliferator-activated receptor gamma (PPARG) polymorphism is associated with zoledronic acid-related osteonecrosis of the jaw in multiple myeloma patients: analysis by DMET microarray profiling
Figures


Similar articles
-
[Avascular osteonecrosis of the jaws induced by diphosphonates].Therapie. 2006 Jul-Aug;61(4):363-5. doi: 10.2515/therapie:2006061. Therapie. 2006. PMID: 17124954 French. No abstract available.
-
Osteonecrosis of the jaws in newly diagnosed multiple myeloma patients treated with zoledronic acid and thalidomide-dexamethasone.Blood. 2006 Dec 1;108(12):3951-2. doi: 10.1182/blood-2006-07-033571. Blood. 2006. PMID: 17114572 Clinical Trial. No abstract available.
-
[Osteonecrosis associated with the use of biphosphonates: Case report].Rev Med Chil. 2006 Sep;134(9):1161-5. doi: 10.4067/s0034-98872006000900011. Epub 2006 Dec 12. Rev Med Chil. 2006. PMID: 17171218 Spanish.
-
Osteonecrosis of jaw in patient with hormone-refractory prostate cancer treated with zoledronic acid.Urology. 2005 Sep;66(3):658. doi: 10.1016/j.urology.2005.03.028. Urology. 2005. PMID: 16140106 Review.
-
Bisphosphonate-related osteonecrosis: genetic and acquired risk factors.Oral Dis. 2009 Sep;15(6):382-7. doi: 10.1111/j.1601-0825.2009.01568.x. Epub 2009 Apr 22. Oral Dis. 2009. PMID: 19413677 Review.
Cited by
-
Genetic variants associated with gastrointestinal symptoms in Fabry disease.Oncotarget. 2016 Dec 27;7(52):85895-85904. doi: 10.18632/oncotarget.13135. Oncotarget. 2016. PMID: 27825144 Free PMC article.
-
Osteonecrosis of the Jaw and Antiresorptive Agents in Benign and Malignant Diseases: A Critical Review Organized by the ECTS.J Clin Endocrinol Metab. 2022 Apr 19;107(5):1441-1460. doi: 10.1210/clinem/dgab888. J Clin Endocrinol Metab. 2022. PMID: 34922381 Free PMC article. Review.
-
Medical treatment of orthotopic glioblastoma with transferrin-conjugated nanoparticles encapsulating zoledronic acid.Oncotarget. 2014 Nov 15;5(21):10446-59. doi: 10.18632/oncotarget.2182. Oncotarget. 2014. PMID: 25431953 Free PMC article.
-
Genetic variants associated with Fabry disease progression despite enzyme replacement therapy.Oncotarget. 2017 Nov 18;8(64):107558-107564. doi: 10.18632/oncotarget.22505. eCollection 2017 Dec 8. Oncotarget. 2017. PMID: 29296186 Free PMC article.
-
Genetic Background of Medication-Related Osteonecrosis of the Jaw: Current Evidence and Future Perspectives.Int J Mol Sci. 2024 Sep 29;25(19):10488. doi: 10.3390/ijms251910488. Int J Mol Sci. 2024. PMID: 39408816 Free PMC article. Review.
References
-
- Ackert-Bicknell CL, Demissie S, Marín de Evsikova C, Hsu YH, DeMambro VE, Karasik D, Cupples LA, Ordovas JM, Tucker KL, Cho K, Canalis E, Paigen B, Churchill GA, Forejt J, Beamer WG, Ferrari S, Bouxsein ML, Kiel DP, Rosen CJ. PPARG by dietary fat interaction influences bone mass in mice and humans. Journal of Bone and Mineral Research. 2008;23:1398–1408. - PMC - PubMed
-
- Dallongeville J, Iribarren C, Ferrières J, Lyon L, Evans A, Go AS, Arveiler D, Fortmann SP, Ducimetière P, Hlatky MA, Amouyel P, Southwick A, Quertermous T, Meirhaeghe A. Peroxisome proliferator-activated receptor gamma polymorphisms and coronary heart disease. PPAR Research. 2009;2009:11. doi: 10.1155/2009/543746. - DOI - PMC - PubMed
-
- Deeken J. The Affymetrix DMET platform and pharmacogenetics in drug development. Current Opinion in Molecular Therapeutics. 2009;11:260–268. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical